Chongqing Zhifei Biological Products Co.,Ltd. (300122.SZ) announced that it has recently been informed that the CA111 injection, developed by its controlling subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd. (hereinafter referred to as "Chen'an Biopharmaceutical"), has commenced a Phase I clinical trial in Zhejiang Province.
The CA111 injection, developed by Chen'an Biopharmaceutical, is a dual agonist targeting both the Glucose-dependent insulinotropic polypeptide (GIP) receptor and the Glucagon-like peptide-1 (GLP-1) receptor.
GIP is a 42-amino acid gastrointestinal regulatory peptide that plays a physiological role in glucose homeostasis by stimulating insulin secretion from pancreatic beta-cells in the presence of glucose and by protecting these beta-cells.
GLP-1 is a 37-amino acid peptide that stimulates insulin secretion, protects pancreatic beta-cells, and inhibits glucagon secretion, gastric emptying, and food intake, thereby helping to control blood sugar and body weight.
Dual GIP and GLP-1 receptor agonists can achieve synergistic and complementary mechanisms of action by activating both the GIP and GLP-1 receptors, leading to superior efficacy in lowering blood glucose and reducing body weight.
Compared to single-target drugs in the same class, the synergistic and complementary action of dual agonists can effectively reduce the side effects associated with the medication.
Comments